30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Healthcare Providers & Services

CVS Health Corp (CVS)

Track

Over the last 90 days, CVS Health Corp. has seen significant insider selling, with a net value of over $323 million. This activity is primarily driven by large sell transactions. There were no insider purchases recorded during this period. The stock has experienced a notable price increase of 41.4% in the past 90 days.
Stock chart
Ticker: CVS Exchange: NYS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
ROBBINS LARRY
1 sale — total 34,619,007 USD
Sale 21 May 2026
Value US$4,449,627.11 | Price 111.48 | Shares 1,066
Proposed sale 21 May 2026
Value US$3,840,157.96 | Price 364.47 | Shares 5,948
Proposed sale 20 May 2026
Value US$2,815,796.53 | Price 94.69 | Shares 29,737
Proposed sale 20 May 2026
Value US$214,283.47 | Price 94.69 | Shares 2,263
Sale 20 May 2026
Value US$77,025.52 | Price 96.28 | Shares 800
Sale 20 May 2026
Value US$6,398,204.31 | Price 95.67 | Shares 66,881
Sale 20 May 2026
Value US$14,476,038.22 | Price 94.81 | Shares 152,691
Sale 20 May 2026
Value US$74,559,553.50 | Price 93.48 | Shares 797,628
Sale 19 May 2026
Value US$14,372.18 | Price 95.18 | Shares 151
Sale 19 May 2026
Value US$187,326,935.38 | Price 94.45 | Shares 1,983,387
Sale 8 May 2026
Value US$6,230,378.58 | Price 89.58 | Shares 69,551
Proposed sale 8 May 2026
Value US$6,230,719.38 | Price 89.58 | Shares 69,551
Sale 20 Aug 2025
Value US$532,650.00 | Price 71.02 | Shares 7,500
Proposed sale 20 Aug 2025
Value US$532,275.00 | Price 70.97 | Shares 7,500
Buy 5 Jun 2025
Value US$100,009.00 | Price 63.70 | Shares 1,570
Sale 6 May 2025
Value US$10,000,710.00 | Price 66.67 | Shares 150,000
Sale 5 May 2025
Value US$6,595,272.41 | Price 67.99 | Shares 96,999
Sale 5 May 2025
Value US$82,654,672.72 | Price 67.37 | Shares 1,226,933
Sale 2 May 2025
Value US$26,035,591.55 | Price 69.66 | Shares 373,776
Sale 2 May 2025
Value US$15,218,980.18 | Price 68.38 | Shares 222,556
Sale 2 May 2025
Value US$113,190,186.18 | Price 67.39 | Shares 1,679,736
Sale 5 Mar 2025
Value US$498,487.55 | Price 66.35 | Shares 7,513
Proposed sale 5 Mar 2025
Value US$498,489.05 | Price 66.35 | Shares 7,513
Buy 18 Feb 2025
Value US$2,001,000.00 | Price 66.70 | Shares 30,000
Buy 23 Jan 2025
Value US$1,288.80 | Price 53.70 | Shares 24
Buy 23 Oct 2024
Value US$1,989.75 | Price 56.85 | Shares 35
Buy 2 Oct 2024
Value US$622.40 | Price 62.24 | Shares 10
Buy 9 Sep 2024
Value US$1,976.45 | Price 56.47 | Shares 35
Buy 2 May 2024
Value US$53,879.00 | Price 53.88 | Shares 1,000
Buy 2 May 2024
Value US$500,293.81 | Price 54.49 | Shares 9,181
Proposed sale 16 Feb 2024
Value US$2,267,923.77 | Price 76.95 | Shares 29,473
Sale 16 Feb 2024
Value US$2,267,947.35 | Price 76.95 | Shares 29,473
Buy 3 Nov 2023
Value US$140,930.00 | Price 70.47 | Shares 2,000
Sale 3 Aug 2023
Value US$1,733,212.32 | Price 74.94 | Shares 23,128
Sale 3 Aug 2023
Value US$196,791.56 | Price 74.79 | Shares 2,631
Proposed sale 3 Aug 2023
Value US$1,929,929.50 | Price 74.92 | Shares 25,759
Buy 3 May 2023
Value US$976,567.20 | Price 69.75 | Shares 14,000
Planned sale 15 Dec 2022
Value US$3,584,868.82 | Price 98.24 | Shares 36,490
Planned sale 15 Dec 2022
Value US$9,936,311.04 | Price 98.40 | Shares 100,976
Planned sale 4 Aug 2022
Value US$2,344,264.00 | Price 104.00 | Shares 22,541
Planned sale 3 Aug 2022
Value US$4,949,098.00 | Price 98.00 | Shares 50,501
Planned sale 3 Aug 2022
Value US$6,899,004.00 | Price 98.00 | Shares 70,398
Planned sale 3 Aug 2022
Value US$954,600.00 | Price 100.00 | Shares 9,546
Planned sale 8 Apr 2022
Value US$328,650.00 | Price 105.00 | Shares 3,130
Planned sale 8 Apr 2022
Value US$430,815.00 | Price 105.00 | Shares 4,103
Planned sale 8 Apr 2022
Value US$600,495.00 | Price 105.00 | Shares 5,719
Planned sale 8 Apr 2022
Value US$331,485.00 | Price 105.00 | Shares 3,157
Planned sale 8 Apr 2022
Value US$88,725.00 | Price 105.00 | Shares 845
Planned sale 5 Apr 2022
Value US$594,100.00 | Price 100.00 | Shares 5,941
Planned sale 4 Apr 2022
Value US$1,204,764.16 | Price 100.13 | Shares 12,032
Planned sale 4 Apr 2022
Value US$2,720,131.58 | Price 100.13 | Shares 27,166
Planned sale 4 Apr 2022
Value US$1,618,200.93 | Price 100.13 | Shares 16,161
Sale 17 Mar 2022
Value US$313,017.75 | Price 106.65 | Shares 2,935
Sale 17 Mar 2022
Value US$180,131.85 | Price 106.65 | Shares 1,689
Sale 15 Mar 2022
Value US$5,392,905.00 | Price 105.00 | Shares 51,361
Buy 10 Feb 2022
Value US$105,904.40 | Price 105.90 | Shares 1,000
Planned sale 3 Feb 2022
Value US$5,273,070.00 | Price 110.00 | Shares 47,937
Planned sale 1 Feb 2022
Value US$2,277,566.23 | Price 106.50 | Shares 21,386
Planned sale 28 Jan 2022
Value US$660,431.00 | Price 109.00 | Shares 6,059
Planned sale 27 Jan 2022
Value US$7,361,815.00 | Price 107.50 | Shares 68,482
Planned sale 3 Nov 2021
Value US$10,342,650.00 | Price 95.00 | Shares 108,870
Sale 1 Nov 2021
Value US$2,534,310.00 | Price 90.00 | Shares 28,159
Planned sale 26 Oct 2021
Value US$7,110,576.00 | Price 88.00 | Shares 80,802
Sale 26 Oct 2021
Value US$172,040.00 | Price 88.00 | Shares 1,955
Planned sale 28 Jun 2021
Value US$232,686.27 | Price 83.67 | Shares 2,781
Planned sale 15 Jun 2021
Value US$5,809,472.00 | Price 86.00 | Shares 67,552
Planned sale 7 Jun 2021
Value US$3,255,640.40 | Price 86.60 | Shares 37,594
Planned sale 10 May 2021
Value US$9,414,334.00 | Price 86.00 | Shares 109,469
Planned sale 7 May 2021
Value US$796,068.00 | Price 84.00 | Shares 9,477
Planned sale 4 May 2021
Value US$392,400.00 | Price 80.00 | Shares 4,905
Planned sale 21 Apr 2021
Value US$186,340.00 | Price 77.00 | Shares 2,420
Planned sale 21 Apr 2021
Value US$7,777,231.00 | Price 77.00 | Shares 101,003
Planned sale 31 Mar 2021
Value US$406,600.00 | Price 76.00 | Shares 5,350
Planned sale 29 Mar 2021
Value US$4,793,109.45 | Price 76.15 | Shares 62,943
Planned sale 26 Mar 2021
Value US$20,225,674.50 | Price 74.73 | Shares 270,650
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-21 2026-05-21 S Sale
3.3
ROBBINS LARRY
Non-Executive Director
1,066 -0.9%
111.48
US$4,449,627 		1,066 -0.9% 111.48 US$4,449,627
2026-05-21 2026-05-21 PrS Proposed sale
1.3
FARAH ROGER N

Director

Non-Executive Director
5,948
364.47
US$3,840,158 		5,948 364.47 US$3,840,158
2026-05-22 2026-05-20 PrS Proposed sale
3.2
AGUIRRE FERNANDO

Director

Non-Executive Director
17,807
226.34
US$2,563,690 		17,807 226.34 US$2,563,690
2026-05-22 2026-05-20 PrS Proposed sale
3.2
AGUIRRE FERNANDO

Director

Non-Executive Director
2,263
94.69
US$214,283 		2,263 94.69 US$214,283
2026-05-21 2026-05-20 S Sale
3.3
ROBBINS LARRY
Non-Executive Director
800 -0.0%
96.28
US$77,026 		800 -0.0% 96.28 US$77,026
2026-05-21 2026-05-20 S Sale
3.3
ROBBINS LARRY
Non-Executive Director
66,881 -1.3%
95.67
US$6,398,204 		66,881 -1.3% 95.67 US$6,398,204
2026-05-21 2026-05-20 S Sale
3.3
ROBBINS LARRY
Non-Executive Director
152,691 -2.8%
94.81
US$14,476,038 		152,691 -2.8% 94.81 US$14,476,038
2026-05-21 2026-05-20 S Sale
3.3
ROBBINS LARRY
Non-Executive Director
797,628 -12.8%
93.48
US$74,559,554 		797,628 -12.8% 93.48 US$74,559,554
2026-05-21 2026-05-19 S Sale
3.3
ROBBINS LARRY
Non-Executive Director
151 -0.0%
95.18
US$14,372 		151 -0.0% 95.18 US$14,372
2026-05-21 2026-05-19 S Sale
3.3
ROBBINS LARRY
Non-Executive Director
1,983,387 -24.2%
94.45
US$187,326,935 		1,983,387 -24.2% 94.45 US$187,326,935
2026-05-11 2026-05-08 S Sale
Mandadi Tilak

EVP, Chief Exp & Tech Officer

Officer
69,551 -87.3%
89.58
US$6,230,379 		69,551 -87.3% 89.58 US$6,230,379
2026-05-08 2026-05-08 PrS Proposed sale
TILAK MANDADI

Officer

Officer
69,551
89.58
US$6,230,719 		69,551 89.58 US$6,230,719
2025-08-29 2025-08-20 S Sale
0.8
Finucane Anne A.
Non-Executive Director
7,500 -25.3%
71.02
US$532,650 		7,500 -25.3% 71.02 US$532,650
2025-08-19 2025-08-20 PrS Proposed sale
0.8
Finucane Anne A.

Director

Non-Executive Director
7,500
70.97
US$532,275 		7,500 70.97 US$532,275
2025-06-09 2025-06-05 B Purchase
3.1
SANSONE GUY P
Non-Executive Director
1,570 +15.0%
63.70
US$100,009 		1,570 +15.0% 63.70 US$100,009
2025-05-06 2025-05-06 S Sale
3.3
ROBBINS LARRY
Non-Executive Director
150,000 -1.8%
66.67
US$10,000,710 		150,000 -1.8% 66.67 US$10,000,710
2025-05-06 2025-05-05 S Sale
3.3
ROBBINS LARRY
Non-Executive Director
96,999 -1.1%
67.99
US$6,595,272 		96,999 -1.1% 67.99 US$6,595,272
2025-05-06 2025-05-05 S Sale
3.3
ROBBINS LARRY
Non-Executive Director
1,226,933 -12.7%
67.37
US$82,654,673 		1,226,933 -12.7% 67.37 US$82,654,673
2025-05-06 2025-05-02 S Sale
3.3
ROBBINS LARRY
Non-Executive Director
373,776 -3.7%
69.66
US$26,035,592 		373,776 -3.7% 69.66 US$26,035,592
2025-05-06 2025-05-02 S Sale
3.3
ROBBINS LARRY
Non-Executive Director
222,556 -2.2%
68.38
US$15,218,980 		222,556 -2.2% 68.38 US$15,218,980
2025-05-06 2025-05-02 S Sale
3.3
ROBBINS LARRY
Non-Executive Director
1,679,736 -14.1%
67.39
US$113,190,186 		1,679,736 -14.1% 67.39 US$113,190,186
2025-03-07 2025-03-05 S Sale
3.6
Clark James David

SVP, Cont & Chief Acct Officer

Officer
7,513 -47.2%
66.35
US$498,488 		7,513 -47.2% 66.35 US$498,488
2025-03-05 2025-03-05 PrS Proposed sale
3.6
Clark James David

Officer

Officer
7,513
66.35
US$498,489 		7,513 66.35 US$498,489
2025-02-19 2025-02-18 B Purchase
2.8
Mahoney Michael F
Non-Executive Director
30,000 +320.6%
66.70
US$2,001,000 		30,000 +320.6% 66.70 US$2,001,000
2026-01-27 2025-01-23 B Purchase
3.1
Nelson Steven H

EVP and President, Aetna

Officer
24 +inf%
53.70
US$1,289 		24 +inf% 53.70 US$1,289
2025-10-14 2024-10-23 B Purchase
3.6
CAPOZZI HEIDI B

EVP and Chief People Officer

Officer
35 +70.0%
56.85
US$1,990 		35 +70.0% 56.85 US$1,990
2025-10-14 2024-10-02 B Purchase
3.6
CAPOZZI HEIDI B

EVP and Chief People Officer

Officer
10 +25.0%
62.24
US$622 		10 +25.0% 62.24 US$622
2025-10-14 2024-09-09 B Purchase
3.6
CAPOZZI HEIDI B

EVP and Chief People Officer

Officer
35 +700.0%
56.47
US$1,976 		35 +700.0% 56.47 US$1,976
2024-05-02 2024-05-02 B Purchase
3.2
LUDWIG EDWARD J
Non-Executive Director
1,000 +4.8%
53.88
US$53,879 		1,000 +4.8% 53.88 US$53,879
2024-05-02 2024-05-02 B Purchase
2.8
Mahoney Michael F
Non-Executive Director
9,181 +5246.3%
54.49
US$500,294 		9,181 +5246.3% 54.49 US$500,294
2024-02-16 2024-02-16 PrS Proposed sale
3.1
PREM S SHAH

Officer

Officer
29,473
76.95
US$2,267,924 		29,473 76.95 US$2,267,924
2024-02-16 2024-02-16 S Sale
3.1
Shah Prem S

EVP and Pres-Pharm, Consumer W

Officer
29,473 -42.6%
76.95
US$2,267,947 		29,473 -42.6% 76.95 US$2,267,947
2023-11-06 2023-11-03 B Purchase
3.2
LUDWIG EDWARD J
Non-Executive Director
2,000 +10.7%
70.47
US$140,930 		2,000 +10.7% 70.47 US$140,930
2023-08-04 2023-08-03 S Sale
3.6
Clark James David

SVP, Cont & Chief Acct Officer

Officer
23,128 -83.1%
74.94
US$1,733,212 		23,128 -83.1% 74.94 US$1,733,212
2023-08-04 2023-08-03 S Sale
3.6
Clark James David

SVP, Cont & Chief Acct Officer

Officer
2,631 -8.6%
74.79
US$196,792 		2,631 -8.6% 74.79 US$196,792
2023-08-03 2023-08-03 PrS Proposed sale
3.6
Clark James David

Officer

Officer
25,759
74.92
US$1,929,930 		25,759 74.92 US$1,929,930
2023-05-05 2023-05-03 B Purchase
2.1
Lynch Karen S

President and CEO

Executive Director
14,000 +3.4%
69.75
US$976,567 		14,000 +3.4% 69.75 US$976,567
2022-12-16 2022-12-15 PlS Planned sale
2.8
Moriarty Thomas M

EVP & General Counsel

Officer
36,490 -5.7%
98.24
US$3,584,869 		36,490 -5.7% 98.24 US$3,584,869
2022-12-16 2022-12-15 PlS Planned sale
2.8
Moriarty Thomas M

EVP & General Counsel

Officer
100,976 -14.2%
98.40
US$9,936,311 		100,976 -14.2% 98.40 US$9,936,311
2022-08-05 2022-08-04 PlS Planned sale
2.3
Lotvin Alan

EVP&President-PharmacyServices

Officer
22,541 -17.1%
104.00
US$2,344,264 		22,541 -17.1% 104.00 US$2,344,264
2022-08-05 2022-08-03 PlS Planned sale
2.3
Lotvin Alan

EVP&President-PharmacyServices

Officer
50,501 -31.6%
98.00
US$4,949,098 		50,501 -31.6% 98.00 US$4,949,098
2022-08-05 2022-08-03 PlS Planned sale
2.3
Lotvin Alan

EVP&President-PharmacyServices

Officer
70,398 -39.2%
98.00
US$6,899,004 		70,398 -39.2% 98.00 US$6,899,004
2022-08-05 2022-08-03 PlS Planned sale
Finke Daniel P

EVP/Pres, Health Care Benefits

Officer
9,546 -22.9%
100.00
US$954,600 		9,546 -22.9% 100.00 US$954,600
2022-04-12 2022-04-08 PlS Planned sale
3.1
Shah Prem S

EVP and Co-President of Retail

Officer
3,130 -6.7%
105.00
US$328,650 		3,130 -6.7% 105.00 US$328,650
2022-04-12 2022-04-08 PlS Planned sale
3.1
Shah Prem S

EVP and Co-President of Retail

Officer
4,103 -8.1%
105.00
US$430,815 		4,103 -8.1% 105.00 US$430,815
2022-04-12 2022-04-08 PlS Planned sale
3.1
Shah Prem S

EVP and Co-President of Retail

Officer
5,719 -10.9%
105.00
US$600,495 		5,719 -10.9% 105.00 US$600,495
2022-04-12 2022-04-08 PlS Planned sale
3.1
Shah Prem S

EVP and Co-President of Retail

Officer
3,157 -6.3%
105.00
US$331,485 		3,157 -6.3% 105.00 US$331,485
2022-04-12 2022-04-08 PlS Planned sale
3.1
Shah Prem S

EVP and Co-President of Retail

Officer
845 -1.8%
105.00
US$88,725 		845 -1.8% 105.00 US$88,725
2022-04-06 2022-04-05 PlS Planned sale
Finke Daniel P

EVP/Pres, Health Care Benefits

Officer
5,941 -15.6%
100.00
US$594,100 		5,941 -15.6% 100.00 US$594,100
2022-04-06 2022-04-04 PlS Planned sale
Finke Daniel P

EVP/Pres, Health Care Benefits

Officer
12,032 -24.0%
100.13
US$1,204,764 		12,032 -24.0% 100.13 US$1,204,764
2022-04-06 2022-04-04 PlS Planned sale
Finke Daniel P

EVP/Pres, Health Care Benefits

Officer
27,166 -35.1%
100.13
US$2,720,132 		27,166 -35.1% 100.13 US$2,720,132
2022-04-06 2022-04-04 PlS Planned sale
Finke Daniel P

EVP/Pres, Health Care Benefits

Officer
16,161 -24.4%
100.13
US$1,618,201 		16,161 -24.4% 100.13 US$1,618,201
2022-03-18 2022-03-17 S Sale
3.1
Shah Prem S

EVP and Co-President of Retail

Officer
2,935 -4.7%
106.65
US$313,018 		2,935 -4.7% 106.65 US$313,018
2022-03-18 2022-03-17 S Sale
3.1
Shah Prem S

EVP and Co-President of Retail

Officer
1,689 -2.8%
106.65
US$180,132 		1,689 -2.8% 106.65 US$180,132
2022-03-17 2022-03-15 S Sale
2.8
Moriarty Thomas M

EVP & General Counsel

Officer
51,361 -5.8%
105.00
US$5,392,905 		51,361 -5.8% 105.00 US$5,392,905
2022-02-11 2022-02-10 B Purchase
3.2
LUDWIG EDWARD J
Non-Executive Director
1,000 +5.8%
105.90
US$105,904 		1,000 +5.8% 105.90 US$105,904
2022-02-04 2022-02-03 PlS Planned sale
1.6
Brennan Troyen A

EVP and Chief Medical Officer

Officer
47,937 -25.7%
110.00
US$5,273,070 		47,937 -25.7% 110.00 US$5,273,070
2022-02-02 2022-02-01 PlS Planned sale
2.3
Lotvin Alan

EVP&President-PharmacyServices

Officer
21,386 -25.9%
106.50
US$2,277,566 		21,386 -25.9% 106.50 US$2,277,566
2022-02-01 2022-01-28 PlS Planned sale
3.6
Clark James David

SVP, Cont & Chief Acct Officer

Officer
6,059 -25.7%
109.00
US$660,431 		6,059 -25.7% 109.00 US$660,431
2022-01-28 2022-01-27 PlS Planned sale
Roberts Jonathan C

EVP & Chief Operating Officer

Officer
68,482 -39.0%
107.50
US$7,361,815 		68,482 -39.0% 107.50 US$7,361,815
2021-11-05 2021-11-03 PlS Planned sale
Roberts Jonathan C

EVP & Chief Operating Officer

Officer
108,870 -50.4%
95.00
US$10,342,650 		108,870 -50.4% 95.00 US$10,342,650
2021-11-03 2021-11-01 S Sale
1.6
Brennan Troyen A

EVP and Chief Medical Officer

Officer
28,159 -16.9%
90.00
US$2,534,310 		28,159 -16.9% 90.00 US$2,534,310
2021-10-28 2021-10-26 PlS Planned sale
1.6
Brennan Troyen A

EVP and Chief Medical Officer

Officer
80,802 -36.9%
88.00
US$7,110,576 		80,802 -36.9% 88.00 US$7,110,576
2021-10-28 2021-10-26 S Sale
1.6
Brennan Troyen A

EVP and Chief Medical Officer

Officer
1,955 -0.9%
88.00
US$172,040 		1,955 -0.9% 88.00 US$172,040
2021-06-29 2021-06-28 PlS Planned sale
2.3
Lotvin Alan

EVP&President-PharmacyServices

Officer
2,781 -4.4%
83.67
US$232,686 		2,781 -4.4% 83.67 US$232,686
2021-06-17 2021-06-15 PlS Planned sale
1.6
Brennan Troyen A

EVP and Chief Medical Officer

Officer
67,552 -32.1%
86.00
US$5,809,472 		67,552 -32.1% 86.00 US$5,809,472
2021-06-08 2021-06-07 PlS Planned sale
Finke Daniel P

EVP/Pres, Health Care Benefits

Officer
37,594 -61.7%
86.60
US$3,255,640 		37,594 -61.7% 86.60 US$3,255,640
2021-05-12 2021-05-10 PlS Planned sale
2.8
Moriarty Thomas M

EVP & General Counsel

Officer
109,469 -100.0%
86.00
US$9,414,334 		109,469 -100.0% 86.00 US$9,414,334
2021-05-10 2021-05-07 PlS Planned sale
1.6
Brennan Troyen A

EVP and Chief Medical Officer

Officer
9,477 -6.1%
84.00
US$796,068 		9,477 -6.1% 84.00 US$796,068
2021-05-06 2021-05-04 PlS Planned sale
2.3
Boratto Eva C

EVP & CFO

Officer
4,905 -4.1%
80.00
US$392,400 		4,905 -4.1% 80.00 US$392,400
2021-04-23 2021-04-21 PlS Planned sale
2.8
Moriarty Thomas M

EVP & General Counsel

Officer
2,420 -100.0%
77.00
US$186,340 		2,420 -100.0% 77.00 US$186,340
2021-04-23 2021-04-21 PlS Planned sale
2.8
Moriarty Thomas M

EVP & General Counsel

Officer
101,003 -97.7%
77.00
US$7,777,231 		101,003 -97.7% 77.00 US$7,777,231
2021-04-01 2021-03-31 PlS Planned sale
3.6
Clark James David

SVP, Cont & Chief Acct Officer

Officer
5,350 -42.5%
76.00
US$406,600 		5,350 -42.5% 76.00 US$406,600
2021-03-30 2021-03-29 PlS Planned sale
2.8
Moriarty Thomas M

EVP & General Counsel

Officer
62,943 -100.0%
76.15
US$4,793,109 		62,943 -100.0% 76.15 US$4,793,109
2021-03-29 2021-03-26 PlS Planned sale
MERLO LARRY J
Non-Executive Director
270,650 -34.1%
74.73
US$20,225,674 		270,650 -34.1% 74.73 US$20,225,674
Explore more

More insider trading research around CVS Health Corp

More insider trades in United States
Similar Healthcare companies with insider activity
More Healthcare Services companies with insider activity
More Healthcare Providers & Services companies with insider activity
Insider trading in North America
Insider trades in S&P 500